Research programme: synthetic biology therapeutics - Synlogic

Drug Profile

Research programme: synthetic biology therapeutics - Synlogic

Alternative Names: SYN-PKU; SYNB 1020; SYNB 1618; Synthetic Biotic™ - Synlogic

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Synlogic
  • Developer AbbVie; Synlogic
  • Class Probiotics
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatic encephalopathy; Inborn urea cycle disorders; Phenylketonuria
  • Research Acidaemia; Cancer; Inflammatory bowel diseases; Maple syrup urine disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 23 May 2017 Early research in Acidaemia in USA (PO)
  • 23 May 2017 Early research in Cancer in USA (PO)
  • 23 May 2017 Early research in Maple syrup urine disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top